subscribeSubscribe
Cassava Announces Completion of Safety Review of Oral Simufilam Pha 3 Trials

Cassava Announces Completion of Safety Review of Oral Simufilam Pha 3 Trials
GLOBENEWSWIRE
25 Mar 2024
Share Share
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam

Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam
GLOBENEWSWIRE
06 Nov 2023
Share Share
MRI Data Suggest Simufilam is Not Associated with ARIA

MRI Data Suggest Simufilam is Not Associated with ARIA
GLOBENEWSWIRE
25 Oct 2023
Share Share
Cassava Completes Patient Enrollment for Phase 3 Trial of Oral Simufilam

Cassava Completes Patient Enrollment for Phase 3 Trial of Oral Simufilam
GLOBENEWSWIRE
02 Oct 2023
Share Share
Cassava Announces Positive Safety Review of Simufilam Phase 3 Trials

Cassava Announces Positive Safety Review of Simufilam Phase 3 Trials
GLOBENEWSWIRE
18 Sep 2023
Share Share
Cassava Announces Publication That Confirms Mechanism of Action of Simufilam

Cassava Announces Publication That Confirms Mechanism of Action of Simufilam
GLOBENEWSWIRE
11 Sep 2023
Share Share
Oral Simufilam Slowed Cognitive Decline in a Trial of Alzheimer`s Disease

Oral Simufilam Slowed Cognitive Decline in a Trial of Alzheimer`s Disease
GLOBENEWSWIRE
05 Jul 2023
Share Share
Why Shares of Cassava Sciences Jumped This Week

Why Shares of Cassava Sciences Jumped This Week
Jim Halley FOOL
12 May 2023
Share Share
Cassava Completes Patient Dosing in a Randomized Controlled Trial of Simufilam

Cassava Completes Patient Dosing in a Randomized Controlled Trial of Simufilam
GLOBENEWSWIRE
11 May 2023
Share Share
Cassava Announces Patient Enrollment Update for Phase 3 Studies of Simufilam

Cassava Announces Patient Enrollment Update for Phase 3 Studies of Simufilam
GLOBENEWSWIRE
08 Feb 2023
Share Share